Could Fenebrutinib Start a New Era for Primary Progressive MS?

Fenebrutinib is drawing attention as one of the new treatment candidates in the field of primary progressive multiple sclerosis (PPMS). The results of the Phase 3 FENtrepid study shared at ACTRIMS Forum 2026 showed that this oral drug provided important data when compared with ocrelizumab, one of the current standard options. According to Roche’s statement, fenebrutinib demonstrated non-inferiority to ocrelizumab on the study’s primary endpoint.

PPMS is one of the most challenging subtypes of MS. This is because the disease often progresses with insidious and continuous worsening rather than clear relapses. For this reason, the limited treatment options make strong data on new drug candidates highly valuable for both patients and clinicians. Ocrelizumab is currently one of the main approved treatments for PPMS, and comparing new candidates with this standard carries particular importance.

In this article, we will discuss What Is Fenebrutinib, What Is Primary Progressive MS, what the study results suggest, which safety points stand out, and what this development means clinically. This content is for informational purposes only; diagnosis and treatment planning require evaluation by a neurology specialist.

What Is Primary Progressive MS (PPMS)?

Primary progressive MS is the type of MS that progresses from the onset of the disease without clear relapse-remission periods. In this picture, loss of neurological function may increase slowly but continuously over time. Walking, balance, hand-arm use, and daily living activities may become increasingly affected. The FDA prescribing information for ocrelizumab also reflects that PPMS is handled as a distinct clinical group and highlights the importance of the treatment need in this area.

In PPMS, the main goal is not only to relieve symptoms but also to slow disability progression as much as possible. However, the limited number of disease-modifying treatment options in this field for many years has made new research much more important. For this reason, fenebrutinib data are seen not only as news of a new molecule, but also as a sign of possible expansion in the treatment landscape.

What Is Fenebrutinib?

Fenebrutinib is a selective and reversible Bruton’s tyrosine kinase inhibitor taken orally. In Roche’s ACTRIMS 2026 presentation, it was emphasized that the drug is an oral BTK inhibitor capable of penetrating the brain. This feature makes the drug particularly noteworthy in terms of progressive MS biology.

This drug aims to target mechanisms involved in disease progression by affecting certain cellular pathways related to the immune system. However, the important point here is this: fenebrutinib is not yet an approved treatment for routine use. Roche stated that the regulatory filing is planned together with other Phase 3 data.

What Did the FENtrepid Study Examine?

FENtrepid is a Phase 3, multicenter, randomized, double-blind study comparing the efficacy and safety of fenebrutinib and ocrelizumab in adults with PPMS. According to data published by Roche, this study is an important investigation in which fenebrutinib was evaluated against ocrelizumab as an active comparator in the PPMS field.

What makes the study notable is that the drug was tested not only against placebo, but directly against the current standard treatment. This increases the clinical value of the results. Because the question here is not only “Is it effective?” but also “How does it perform against the current treatment?”

What Was the Main Objective of the Study?

The primary objective of the study was to evaluate to what extent it could slow disability progression. In the ACTRIMS presentation, the primary endpoint was stated as 12-week confirmed composite disability progression. Measurements included EDSS, the timed walking test, and the 9-hole peg test.

This approach is important because in PPMS, not only walking but also upper extremity functions directly affect quality of life. Loss of hand-arm function can have serious consequences on daily independence. Therefore, not only overall progression but also changes in specific functional areas are considered clinically meaningful.

What Did the Fenebrutinib Study Results Show?

According to the results shared at ACTRIMS 2026, fenebrutinib demonstrated non-inferiority to ocrelizumab on the primary endpoint in reducing disability progression in PPMS. Roche also reported that fenebrutinib numerically showed a lower risk of disability progression starting from week 24.

In additional analyses, notable signals emerged especially in terms of upper extremity function. The presentation reported that the strongest effect was seen in the 9-hole peg test, and that some analyses showed a risk reduction signal of more than 20% in favor of fenebrutinib. For this reason, the drug is thought to be potentially important not only for overall progression but also in critical areas of daily life such as hand-arm function.

Clinical Importance of the Results

The most important aspect of these data is that an oral treatment candidate in PPMS showed meaningful performance against a strong active comparator. Moreover, the signals that stood out in upper extremity functions are especially valuable in clinical practice for preserving patients’ independence.

Still, these results should be interpreted in a balanced way. The regulatory process for fenebrutinib has not yet been completed. In addition, long-term real-world data are still limited. Therefore, the current picture does not mean that “the standard treatment has immediately changed”; rather, it suggests that a strong candidate is approaching clinical use.

What Do the Safety Data Say?

According to the ACTRIMS 2026 presentation, the rates of adverse events and serious adverse events were generally comparable between the two groups. Infection rates were also reported to be similar. However, elevations in liver enzymes were observed more frequently in the fenebrutinib arm. In addition, Roche’s presentation noted an imbalance in fatal adverse events; therefore, the safety evaluation will become clearer with long-term follow-up.

At this point, safety data are especially important. Because in chronic and progressive diseases such as PPMS, treatment must not only be effective but also offer a manageable long-term safety profile. Monitoring laboratory parameters such as liver enzymes will play an important role in determining the future place of the drug in clinical practice.

Why Is Fenebrutinib in the Spotlight Compared with Ocrelizumab?

Ocrelizumab is one of the main approved treatment options for PPMS. For this reason, comparing new treatment candidates with ocrelizumab creates a clinically strong reference point. Fenebrutinib’s demonstration of non-inferiority against this standard treatment has made it a much stronger candidate in the research world.

In addition, the advantage of oral use is also drawing attention. Compared with infusion-based treatments, oral options may provide easier access and use for some patients. Of course, the real clinical value of this advantage will be better understood as the approval process, long-term safety data, and day-to-day use experience become clearer.

What Does This Development Mean for Patients?

One of the biggest problems for patients with PPMS is that treatment options have long been limited. For this reason, fenebrutinib data are not just a headline about a new drug; they are also an important development showing that research in the field of progressive MS is gaining momentum. In particular, the increasing visibility of different mechanisms targeting progression creates a promising picture for the coming years.

However, a very clear boundary must be drawn here: patients should not change their current treatment on their own. Fenebrutinib is not yet an approved routine treatment for PPMS. Therefore, its meaning today can be summarized as “a strong and promising development that should be followed closely.”

Conclusion

Fenebrutinib has become one of the most remarkable research topics in the field of primary progressive MS in recent years. The FENtrepid results announced at ACTRIMS 2026 revealed that the drug demonstrated non-inferiority to ocrelizumab and showed signals of additional benefit in some functional measures.

Although it is not yet an approved treatment, fenebrutinib is seen as one of the candidates that could change the future of PPMS treatment. In the coming period, regulatory submissions, long-term safety data, and real-world results will define the drug’s place in clinical practice more clearly. For this reason, it is very important to closely follow new developments in the fields of Fenebrutinib and Primary Progressive MS.

References

• Roche. Roche’s fenebrutinib is the first investigational medicine in over a decade that reduces disability progression in primary progressive multiple sclerosis (PPMS). February 7, 2026.

• Roche Media & Investor Release. Primary results of the Phase III FENtrepid study presented at ACTRIMS Forum 2026. February 2026.

• Roche / ACTRIMS Forum 2026 Presentation. Efficacy and Safety of Fenebrutinib vs Ocrelizumab in Primary Progressive Multiple Sclerosis: Primary Results of the Phase III FENtrepid Study. 2026.

• U.S. Food and Drug Administration. OCREVUS (ocrelizumab) prescribing information. Current label information.